Xilio Therapeutics, Inc.XLONASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank17
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-177.78%
↓ 14% vs avg
Percentile
P17
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
-156.01%
Historical baseline
PeriodValueYoY Change
TTM-177.78%+80.6%
2024-914.27%-
20230.00%-
20220.00%-
20210.00%-
20200.00%-
20190.00%-